Amantadine and rimantadine are compounds of the adamantane class of antivirals which act on influenza A viruses by binding to the M2 ion channel, preventing uncoating of the virus during replication. Treatment of influenza A virus infection with these drugs within 48 hours of symptom onset reduces illness by ca 24 hours, and when given prophylactically, the drugs can prevent ca 60% of influenza cases \[[@r1]\]. However, effectiveness of both drugs is lost when viruses acquire an amino acid substitution at one of five critical residues of the M2 protein i.e. positions 26, 27, 30, 31 and 34 \[[@r2]\]. The occurrence of adamantane-resistant influenza A viruses was rare among circulating influenza viruses \[[@r3]\] until 2000, when an increasing proportion of viruses from Asia, particularly China, contained the serine (S) to asparagine (N) substitution at residue 31 (S31N) of the M2 protein \[[@r4]\]. By the end of the 2005/06 influenza season, over 90% of circulating A(H3N2) viruses in North America and other parts of the northern hemisphere, such as Asia, contained the S31N substitution even though the vast majority of resistant viruses were from patients who had not been treated with adamantanes \[[@r5]\]. After more than 7 years of almost complete dominance of adamantane-resistant A(H3N2) influenza viruses globally, we describe the detection in Australia of increased numbers of adamantane-sensitive viruses during the 2017 influenza season.

Global frequency of adamantane-resistant A(H3N2) viruses 1968--2017
===================================================================

Analysis of all M2 gene sequences of A(H3N2) viruses deposited in the EpiFlu public sequence database of the Global Initiative on Sharing All Influenza Data (GISAID) (n = 26,231; as at 21 November 2017), showed that the global frequency of adamantane-resistant A(H3N2) viruses with M2 N31 has been \> 99% each year from 2010 to 2017 ([Table 1](#t1){ref-type="table"}).

###### Frequency of influenza A(H3N2) viruses with different amino acids at residue 31 of the M2 protein, 1968--2017^a^

  --------------------------------------------------------------------------------------------------------------
  Year(s)      M2 S31\                  M2 N31\                  M2 D31\                                
               (adamantane-sensitive)   (adamantane-resistant)   (adamantane-resistant)                 
  ------------ ------------------------ ------------------------ ------------------------ --------- --- --------
  1968--1999   1,153                    98.3                     20                       1.7       0   0.0

  2000         224                      99.1                     2                        0.9       0   0.0

  2001         112                      99.1                     1                        0.9       0   0.0

  2002         304                      99.0                     3                        1.0       0   0.0

  2003         424                      87.8                     59                       12.2      0   0.0

  2004^b^      341                      77.5                     98                       22.3      0   0.0

  2005         229                      45.1                     279                      54.9      0   0.0

  2006         38                       13.0                     254                      87.0      0   0.0

  2007         85                       12.6                     589                      87.0      3   0.4

  2008         7                        1.2                      597                      98.8      0   0.0

  2009         11                       1.1                      948                      98.9      0   0.0

  2010         9                        0.9                      973                      99.1      0   0.0

  2011         3                        0.2                      1,307                    99.7      1   0.1

  2012         3                        0.2                      1,897                    99.8      0   0.0

  2013         0                        0.0                      1,445                    100.0     0   0.0

  2014         2                        0.1                      1,892                    99.6      5   0.3

  2015         2                        0.1                      3,454                    99.9      1   \< 0.1

  2016         1                        \< 0.1                   4,286                    \> 99.9   1   \< 0.1

  2017^c^      20                       0.4                      5,142                    99.5      5   0.1
  --------------------------------------------------------------------------------------------------------------

^a^ As at 21 November 2017.

^b^ One virus with M2 I31 was detected.

^C^ Includes the Australian viruses reported in this study.

Percentages rounded to one decimal.

The authors acknowledge the originating and submitting laboratories that provided sequences to GISAID's EpiFlu database which were used to calculate the global frequencies of A(H3N2) viruses with different amino acid residues at position 31 of the M2 ([www.gisaid.org](http://www.gisaid.org)).

Analysis of the adamantane-resistance situation in Australia during the 2017 influenza season
=============================================================================================

The Australian 2017 influenza season was dominated by high levels of A(H3N2) influenza virus activity. During this season, 15 adamantane-sensitive A(H3N2) viruses encoding M2 S31 were detected in Australia ([Table 2](#t2){ref-type="table"}), which exceeded the cumulative total of 11 adamantane-sensitive influenza A viruses detected globally between 2011 and 2016 ([Table 1](#t1){ref-type="table"}). In contrast, the frequency of adamantane-resistance in circulating A(H1N1)pdm09 viruses has remained unchanged at \> 99.9% both in Australia and worldwide.

###### Details of M2 S31 and D31 influenza A(H3N2) viruses detected in Australia and New Zealand, July --September 2017 (n=21)

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Virus designation      Location                        Specimen date\   M2 31 residue   Age (years)   Sex       Patient status   GISAID isolate ID
                                                         (2017)                                                                    
  ---------------------- ------------------------------- ---------------- --------------- ------------- --------- ---------------- -----------------------
  A/Wellington/35/2017   Wellington, New Zealand         3 Jul            S               Unknown       Female    Out-patient      EPI_ISL_277612

  A/Victoria/27/2017     Victoria, Australia             3 Jul            D               20            Female    Unknown          EPI_ISL_277591

  A/Victoria/22/2017     Victoria, Australia             4 Jul            S               21            Female    Unknown          EPI_ISL_275249

  A/Victoria/1008/2017   Victoria, Australia             18 Jul           S               27            Male      Unknown          EPI_ISL_277586

  A/Victoria/51/2017     Victoria, Australia             18 Jul           D               77            Male      Unknown          EPI_ISL_277338

  A/Victoria/586/2017    Victoria, Australia             21 Jul           S               Unknown       Unknown   Unknown          EPI_ISL_278020

  A/Victoria/628/2017    Victoria, Australia             4 Aug            S               90            Male      Inpatient        EPI_ISL_277968

  A/Victoria/2069/2017   Victoria, Australia             4 Aug            D               57            Male      Unknown          EPI_ISL_277965

  A/Brisbane/1017/2017   Queensland, Australia           7 Aug            S               31            Female    Outpatient       EPI_ISL_277915

  A/Sydney/1101/2017     New South Wales, Australia      9 Aug            S               84            Female    Unknown          EPI_ISL_283125

  A/Sydney/1079/2017     New South Wales, Australia      9 Aug            S               30            Male      Unknown          EPI_ISL_277907

  A/Victoria/653/2017    Victoria, Australia             10 Aug           S               23            Female    Outpatient       EPI_ISL_277940

  A/Victoria/655/2017    Victoria, Australia             10 Aug           S               82            Male      Outpatient       EPI_ISL_277969

  A/Victoria/624/2017    Victoria, Australia             11 Aug           S               82            Male      Inpatient        EPI_ISL_277922

  A/Brisbane/140/2017    Queensland, Australia           22 Aug           S               2 months      Female    Outpatient       EPI_ISL_283124

  A/Darwin/1016/2017     Northern Territory, Australia   31 Aug           S               42            Male      Unknown          EPI_ISL_283121

  A/Victoria/708/2017    Victoria, Australia             2 Sep            D               8             Female    Outpatient       EPI_ISL_283122

  A/Victoria/697/2017    Victoria, Australia             2 Sep            S               77            Male      Inpatient        EPI_ISL_283119

  A/Victoria/856/2017    Victoria, Australia             18 Sep           D               9             Female    Unknown          Poor sequence quality

  A/Victoria/211/2017    Victoria, Australia             19 Sep           S               68            Male      Deceased         EPI_ISL_283123

  A/Victoria/872/2017    Victoria, Australia             26 Sep           S               58            Female    Unknown          EPI_ISL_283120
  --------------------------------------------------------------------------------------------------------------------------------------------------------

Using Sanger sequencing \[[@r6]\], next generation sequencing \[[@r7]\] or pyrosequencing \[[@r8]\] we found that from 1 March to 30 June 2017, all 310 tested Australian A(H3N2) viruses encoded M2 N31 indicating adamantane-resistance (M2 N31 viruses). However, in July, August and September 2017, two of 201 (1.0%), 10 of 115 (8.7%) and three of 145 (2.1%) tested A(H3N2) virus isolates, respectively, encoded M2 S31 indicating adamantane-sensitivity (M2 S31 viruses). The M2 S31 viruses were detected across four states in Australia (Victoria: n = 10; New South Wales: n = 2; Queensland: n = 2; Northern Territory: n = 1), as well as 1 of 70 tested from New Zealand ([Figure 1](#f1){ref-type="fig"}), indicating that although overall frequency was low, the M2 S31 viruses had spread across a large geographic area ([Table 2](#t2){ref-type="table"}). A(H3N2) influenza viruses tested from the other Australian states of South Australia (n = 148), Western Australia (n = 40), Tasmania (n = 54) and the Australian Capital Territory (n = 32) were all M2 N31 viruses.
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In Victoria, M2 S31 viruses were detected in July, August and September, with the peak detection frequency of five of 35 occurring in August ([Figure 1](#f1){ref-type="fig"}). In addition to the 10 M2 S31 viruses, a further five Victorian A(H3N2) viruses contained an alternative amino acid, aspartic acid (D), at residue 31 of the M2 protein (M2 D31 viruses) ([Figure 1](#f1){ref-type="fig"})([Table 2](#t2){ref-type="table"}). M2 D31 viruses have been extremely rare since the emergence of the A(H3N2) viruses in 1968, with just 11 of 21,064 (0.05%) viruses detected globally before 2017, compared with the detection rate of five of 210 (2.4%) seen between July and September 2017 in Victoria ([Figure 1](#f1){ref-type="fig"}). However, M2 D31 viruses remain adamantane-resistant \[[@r9]\]. Original specimens were available for eight of the M2 S31 or D31 virus isolates, and sequencing confirmed 100% nt match between the isolates/clinical specimen pairs, with no evidence of mixed viral populations at the codon for position 31 of the M2 protein.

Phylogenetic analysis of Australian M2 S31 influenza A(H3N2) viruses
====================================================================

To understand whether the M2 S31 or D31 viruses emerged from a single source or occurred sporadically, phylogenetic trees were constructed using the haemagglutinin (HA), neuraminidase (NA) and M2 gene sequences of the 2017 A(H3N2) viruses from Australia, together with global A(H3N2) virus sequences from March to September 2017 available from GISAID ([Figure 2](#f2){ref-type="fig"}, [Figure 3](#f3){ref-type="fig"} and [Figure 4](#f4){ref-type="fig"}). The authors acknowledge the originating and submitting laboratories that provided sequences to GISAID's EpiFlu database which were used to construct the phylogenetic trees ([www.gisaid.org](http://www.gisaid.org)). In both HA and NA phylogenetic trees all but two of the Australian M2 S31 viruses formed a monophyletic group, together with a Japanese and New Zealand M2 S31 virus. The Japanese virus, A/Mie/18/2017 (isolated in May 2017), was positioned ancestrally to the M2 S31 Australian viruses in both the HA and NA clades ([Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}), suggesting it may have been the progenitor. All of the M2 S31 viruses were part of the HA clade 3C.2a1, except for one strain (A/Victoria/22/2017) from July which was a 3C.2a virus ([Figure 2](#f2){ref-type="fig"}), and all but one (A/Victoria/211/2017) of the 3C.2a1 viruses formed the subclade characterised by HA amino acid substitutions R261Q and K83R ([Figure 2](#f2){ref-type="fig"}), which exclusively contained these viruses even when all A(H3N2) viruses via GISAID were included in the analysis. The M2 D31 viruses clustered together phylogenetically, forming a separate branch within the HA clade 3C.2a1, although this clade also contained some M2 N31 Australian viruses ([Figure 2](#f2){ref-type="fig"}).
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Discussion and conclusion
=========================

Adamantane-resistance was first detected in persons infected with influenza virus who were treated with adamantanes in the late 1980s, in closed settings, such as nursing homes \[[@r10],[@r11]\], as well as community settings \[[@r12]\]. In the latter, there was apparent transmission of drug-resistant strains, when rimantadine was used for treatment or post-exposure prophylaxis in families \[[@r12]\]. Adamantane-resistant viruses were also detected in nursing home patients without exposure to these drugs \[[@r13]\], demonstrating that adamantane-resistant variants may be able to spread in the community. Up to 45% of children treated with rimantadine have been reported to shed resistant viruses \[[@r14]\]. In addition to widespread adamantane-resistance among A(H3N2) influenza viruses circulating globally, seasonal influenza A(H1N1) viruses also developed adamantane-resistance between 2005 and 2008 \[[@r15],[@r16]\], and the A(H1N1)pdm09 virus that emerged and caused the influenza pandemic in 2009 was also adamantane-resistant. As consequence of these developments, adamantanes are no longer recommended for treatment of influenza \[[@r5]\].

The spread of M2 N31 viruses in the early 2000s was thought to be due to linkage to advantageous substitutions elsewhere in the virus, in a process referred to as genetic 'hitch-hiking', and not related to adamantane-induced selection pressure \[[@r17]\]. Even though the A(H3N2) virus has continued to undergo substantial antigenic and genetic evolution over the last decade, the M2 N31 residue has remained almost completely fixed, suggesting that during that time it contributed to viral fitness. However, the recent detection of M2 S31 and D31 viruses in Australia suggests that the importance of the M2 N31 residue in viral fitness may no longer be as strong as it was. We encourage surveillance laboratories, where possible, to conduct M2 sequencing of A(H3N2) viruses during the upcoming 2017/18 northern hemisphere influenza season to see if the M2 S31 or D31 viruses begin to circulate in greater numbers globally.

In the seminal publication by Bright et al. on the emergence of the S31N variant in the early 2000s \[[@r4]\], the authors stated that '*further genetic and antigenic evolution of influenza A(H3N2) viruses resulting in the disappearance of the S31N mutation and reversion back to the drug sensitive phenotype should not be excluded'*. It may be that the M2 S31 viruses detected in Australasia in 2017 could be the progenitors for a reversion back to more widely circulating adamantane-sensitive A(H3N2) viruses, some 12 years after the resistant strain emerged and then dominated globally. If this were the case, it would revive the option of using adamantanes to treat A(H3N2) virus infections and improve the opportunities for using these drugs in combination with other antivirals \[[@r18]\].
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